Drugs / BMS-986463
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06476808 | Sep 2024 → Dec 2028 expected | endometrial serous adenocarcinoma, non-small cell lung carcinoma, ovarian serous adenocarcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986463 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06476808 ↗ |